First Tracks Biotherapeutics
TRAX
31.46
+0.87
+2.84%
First Tracks Biotherapeutics
US · TRAX
#3189 by market cap
Listed 2026
31.46
+0.87
+2.84%
Live - 5344 symbols - heartbeat 260s ago
· 2026-10-08 10:00
Pre-market
32.45
+6.08%
After-hours
29.99
-1.96%
Overnight
31.57
+3.20%
- Market cap
- 1.12B
- P/E (TTM)i
- -6.94
- P/Bi
- 6.66
- EPSi
- -4.92
- Div yieldi
- 0.00%
- 52W posi
- 48%
Reader sentiment
Are you bullish or bearish on TRAX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 3.1 percentage points.
Institutional ownership
- Held by institutions
- 102.96% -3.13pp
- Institutions
- 182 -5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund45.03%
Hedge Fund38.82%
VC/PE Fund10.58%
Public Company7.78%
Individual/Insider1.84%
Private Company0.26%
Sovereign Wealth Fund0.19%
Government Pension Fund0.17%
Insurance Company0.13%
Top holders as of 2026-06-30
EcoR1 Capital, LLC
8.88% · 3.17M sh
TCG Crossover Management, LLC
8.10% · 2.90M sh
Sirenia Capital Management LP
6.98% · 2.50M sh
FMR
5.75% · 2.05M sh
Affinity Asset Advisors, LLC
5.69% · 2.03M sh
BlackRock
5.50% · 1.96M sh
Vanguard Capital Management, LLC
4.60% · 1.64M sh
Trails Edge Capital Partners, LP
4.24% · 1.51M sh
State Street Global Advisors
4.23% · 1.51M sh
Janus Henderson Group plc
3.05% · 1.09M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 45 buys · 3 sells
| Name | Role | Stake |
|---|---|---|
| Daniel Faga | Chief Executive Officer | 1.39% |
| Paul Lizzul | Chief Medical Officer | 0.12% |
| John Schmid | Director | 0.11% |
| Rita Jain | Director | 0.05% |
| John Orwin | Director | 0.05% |
| Magda Marquet | Director | 0.04% |
| J. Ware | Director | 0.04% |
| Dennis Fenton | Director | 0.03% |
| Ajim Tamboli | Chief Financial Officer | -- |
| AnaptysBio, Inc. | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | John Orwin | Director | Derivative Exercise and Retained | +1,300 | -- |
| 2026-09-01 | J. Ware | Director | Derivative Exercise and Sale | -39,265 | $5.74–44.78 |
| 2026-08-14 | Paul Lizzul | Chief Medical Officer | Other Derivative Acquisition | +60,492 | -- |
| 2026-08-14 | Daniel Faga | Chief Executive Officer | Other Derivative Acquisition | +193,575 | -- |
| 2026-08-14 | Benjamin Stone | Chief Business Officer | Other Derivative Acquisition | +60,492 | -- |
| 2026-08-01 | Paul Lizzul | Chief Medical Officer | Other Derivative Acquisition | +60,492 | -- |
| 2026-08-01 | Daniel Faga | Chief Executive Officer | Other Derivative Acquisition | +193,576 | -- |
| 2026-08-01 | Benjamin Stone | Chief Business Officer | Other Derivative Acquisition | +60,492 | -- |
| 2026-06-14 | John Orwin | Director | Derivative Exercise and Retained | +6,030 | -- |
| 2026-06-14 | John Schmid | Director | Derivative Exercise and Retained | +6,030 | -- |
| 2026-06-14 | Dennis Fenton | Director | Derivative Exercise and Retained | +6,030 | -- |
| 2026-06-14 | Magda Marquet | Director | Derivative Exercise and Retained | +6,030 | -- |
| 2026-06-14 | J. Ware | Director | Derivative Exercise and Retained | +6,030 | -- |
| 2026-06-14 | Rita Jain | Director | Derivative Exercise and Retained | +7,330 | -- |
| 2026-05-11 | John Orwin | Director | Other Derivative Acquisition | +2,500 | -- |
| 2026-05-11 | John Orwin | Director | Other Derivative Acquisition | +7,000 | $17.81 |
| 2026-05-11 | John Schmid | Director | Other Derivative Acquisition | +2,500 | -- |
| 2026-05-11 | John Schmid | Director | Other Derivative Acquisition | +7,000 | $17.81 |
| 2026-05-11 | Dennis Fenton | Director | Other Derivative Acquisition | +2,500 | -- |
| 2026-05-11 | Dennis Fenton | Director | Other Derivative Acquisition | +7,000 | $17.81 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:00:16 · For reference only, not investment advice and not tailored to your situation.